Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL (NCT00981799), a non-randomized phase 1, phase 2 study. The primary outcome is To Determine the Presence of Dose-limiting Toxicities (DLTs) of Nelarabine, Etoposide and Cyclophosphamide When Given in Combination to Children With T-ALL and Bone Marrow Relapse or T-LL..

2. Clinical Question

This is a safety and dose-finding question, rather than a randomized test of whether the combination is better than another treatment. The record also lists a secondary objective to determine complete remission rates after 1 and 2 courses, but it does not report remission results. The enrollment was 23. The record does not provide outcome estimates that would show how many evaluable participants experienced DLTs at each dose level, so the primary question cannot be answered from the posted results.

3. Trial Design

The registry record describes a Phase I and Phase II, nonrandomized, unmasked, sequential trial. It was sponsored by the Therapeutic Advances in Childhood Leukemia Consortium. The trial began in 2010-06, had a primary completion date of 2015-11, and is listed as terminated. The reason for termination is not reported in the registry record.

Participants were assigned to nelarabine dose levels in a dose-escalation structure, not randomly allocated to parallel comparison groups. The arm descriptions state that the study would begin at Dose Level 1 and escalate if the maximum tolerated dose was not exceeded. Dose Level 0 was described as an option if the maximum tolerated dose at Dose Level 1 had been exceeded; the primary outcome record says no participants met criteria to enter Dose Level 0. The operational details beyond what is stated in the arm descriptions are not reported in the registry record.

The dose-level groups listed in the adverse-event results include 6 participants at Dose Level 1, 7 at Dose Level 2, 10 at Dose Level 3, and 0 at Dose Level 0. These group sizes describe the recorded groups; they do not establish that every participant contributed evaluable data for the primary outcome. The record explicitly notes that not all participants enrolled at each dose level were assessed as evaluable for DLTs.

Sequential dose finding can support decisions about which doses to investigate, but it does not create a randomized comparison. Participants at different levels may have entered at different points in the sequence, and dose level itself defines the groups. The record does not report an independent control arm, masking, or a randomized allocation process. Further detail on eligibility, treatment timing, and the full protocol is not reported in the registry record.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Overall Study

Reasons for not completing this period:

Analysis population for the primary outcome, as defined in the registry: There are 0 patients for Dose Level 0 as no patients met the criteria to be enrolled

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

Population: Dose Level 0 did not accrue any subjects as the criteria to accrue at Dose Level 0 was not met

6. Primary Endpoint

The registry lists the primary outcome as To Determine the Presence of Dose-limiting Toxicities (DLTs) of Nelarabine, Etoposide and Cyclophosphamide When Given in Combination to Children With T-ALL and Bone Marrow Relapse or T-LL., measured over 6 months.

The primary outcome is the presence of dose-limiting toxicities associated with the combination of nelarabine, etoposide and cyclophosphamide. It is recorded as a count of participants, assessed over a timeframe of 6 months. In a dose-finding trial, DLTs are used to assess whether treatment-related toxicity limits the doses under study. This makes the outcome relevant to the trial’s stated safety and maximum-tolerated-dose objective.

The registry record says participants were evaluated by dose level and total courses taken at each level. It also cautions that not everyone enrolled at a dose level was considered evaluable for DLTs; only those meeting evaluability criteria were included in the overall number analyzed. The criteria and the number deemed evaluable are not reported in the registry record. Consequently, enrollment counts alone do not give the denominator for the primary endpoint.

The posted results do not state the observed DLT counts or the overall analyzed population for this outcome. The endpoint definition therefore explains what the trial intended to assess, but the record does not provide enough outcome information to describe the frequency of DLTs or compare it across dose levels. Complete remission after 1 and 2 courses is listed as a secondary outcome, but its results are also not reported in the registry record.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

The main statistical issue is the distinction between a dose-finding description and a comparative treatment-effect analysis. This trial used sequential, nonrandomized dose levels. Its groups were formed as part of dose escalation, rather than by random assignment to competing treatments. As a general statistical principle, randomization helps balance known and unknown participant characteristics across comparison groups. Without it, differences between dose-level groups can reflect group composition, the sequence of enrollment, exposure, or other factors as well as dose. The registry record does not report an adjusted analysis that would address these possibilities.

What a participant count represents

The primary outcome is a count of participants with DLTs, not a continuous measurement or a time-to-event outcome. To interpret a count as a frequency, the relevant denominator is the number of participants who were actually assessed and considered evaluable. The registry record says that not all participants enrolled at each dose level were evaluable and that only participants meeting DLT-evaluability criteria were counted in the overall number analyzed. Those criteria and the evaluable denominators are not reported. Thus, enrollment totals cannot substitute for the missing primary-outcome denominators, and no DLT rate can be inferred from them.

In general, missing outcome information can arise because a participant did not complete the relevant follow-up, did not meet an assessment criterion, or had incomplete records. These are possible explanations in general, not explanations reported for this trial. The record does not describe why participants were not evaluable, how missing primary outcome information was handled, or whether any imputation was used.

How sequential dose finding differs from a trial comparison

In general, a dose-escalation design uses accumulating safety information to guide which dose level is studied next. The registry arm descriptions state that escalation from Dose Level 1 would occur if the maximum tolerated dose was not exceeded, and describe Dose Level 0 as a possible lower level if the limit at Dose Level 1 was exceeded. However, the available description of the Dose Level 1 decision process is incomplete, and the full escalation algorithm is not reported in the registry record. It is therefore not possible to reconstruct all decision rules or determine how each participant’s outcome affected subsequent enrollment.

Because allocation was nonrandomized and sequential, dose levels should not be interpreted as exchangeable arms in a conventional comparative trial. Even if counts differ, a direct contrast would not by itself show that dose caused the difference. The posted record contains no adjusted or causal analysis to support such an interpretation. No inferential analysis is reported for the primary endpoint.

Precision and uncertainty

In general, a confidence interval describes a range of values compatible with the observed data under a specified statistical model. It conveys uncertainty around an estimate; it does not remove design limitations or establish causation. No confidence intervals for the primary DLT outcome are reported in the registry record. Without the endpoint counts and evaluable denominators, the precision of any DLT frequency cannot be assessed from the record.

In general, small study groups tend to yield less precise estimates than larger groups, particularly when an outcome is uncommon. The recorded dose-level group sizes are 6, 7, and 10 participants for Levels 1, 2, and 3, while no participants entered Level 0. These enrollment counts alone do not determine precision for the primary endpoint because its evaluable denominators and observed outcomes are absent. They also do not support claims about statistical power or whether a difference could be detected.

Over-dispersion and model choice

For count outcomes, a basic statistical model may assume that variation follows a specified distribution. In general, over-dispersion means observed variability is greater than that model expects; if ignored, standard errors may be too small and uncertainty may be understated. This concept is relevant when modeling counts across groups, but the registry record does not report a count model, an over-dispersion assessment, or a model-based estimate. Since the posted primary outcome is participant counts and no statistical analyses are reported, there is no basis to claim that a particular model was used or that over-dispersion affected the findings.

Planning calculations are not trial findings

The sample-size planning illustration uses a two-sided significance level of 0.05, equal allocation between two arms, and a normal approximation, with the effect expressed as a fraction of the observed effect. The stated assumptions are a planning framework, not the study’s observed result or a justification for its enrollment. The registry record does not report the trial’s own sample-size justification. Planning sample sizes, when displayed, are hypothetical illustrations and must not be read as observed power or as evidence that the trial had a particular probability of detecting an effect. The trial was also nonrandomized and sequential, so an equal-allocation two-arm illustration does not describe its actual dose-level enrollment structure.

Overall, the available record supports description of the design, endpoint definition, enrollment groups and selected adverse-event figures. It does not provide the primary outcome data or statistical analyses needed to estimate DLT frequency, precision, or between-level differences.

10. Multiplicity, Missing Data and Analysis Populations

The trial lists a primary safety objective and a secondary objective to determine complete remission rates after 1 and 2 courses. When a study evaluates multiple outcomes, time points, or comparisons, the chance of finding at least one apparently notable result can increase. In general, statistical plans may address this through prespecified outcome hierarchies or multiplicity adjustments. The registry record does not report whether such an approach was planned or used. The remission results are not reported in the registry record, and no statistical analyses are listed.

Missingness is an important issue for the primary outcome because the record explicitly says that not all participants enrolled at each dose level were evaluable for DLTs. It states that only participants meeting DLT-evaluability criteria were counted in the overall number analyzed. The criteria, numbers excluded or unevaluable, reasons for non-evaluability, and method for handling missing assessments are not reported in the registry record. Without these details, it is not possible to determine how complete the endpoint data were or whether the analyzed participants could differ systematically from those not analyzed.

The record identifies dose-level groups for adverse-event reporting but does not establish that the same participants or denominators were used for each outcome. The primary endpoint population is therefore not necessarily identical to the total enrolled population or the adverse-event populations. No intention-to-treat or other named analysis population is described in the registry record. These limitations affect interpretation of both the safety endpoint and the secondary remission objective.

11. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Deaths

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 0% reporting threshold.

Most frequent serious adverse event terms

Most frequent non-serious adverse event terms

Serious events with the highest arm-level rate: febrile neutropenia (40.0%), neuropathy- peripheral motor (20.0%), hypotension (20.0%), allergic reaction (20.0%), infection, perianal (20.0%).

The adverse-event record gives the number at risk and the number affected by serious adverse events for each dose level. At Dose Level 1, 1 of 6 participants is listed as affected; at Dose Level 2, 5 of 7; and at Dose Level 3, 7 of 10. Dose Level 0 has 0 participants at risk and 0 affected. These are descriptive counts, not randomized treatment comparisons. The registry record does not provide enough information to infer that dose level caused differences between groups.

The most frequently listed serious event term is Febrile Neutropenia at 40.0%. Neuropathy- Peripheral Motor, Hypotension, Allergic reaction, and Infection, perianal are each listed at 20.0%, and Hypoalbuminemia at 16.7%. The denominator and group-specific distribution underlying these term percentages are not reported in the registry record, so they should not be interpreted as dose-specific risks.

Deaths are listed as 4 at Dose Level 1, 7 at Dose Level 2, and 8 at Dose Level 3, with 0 at Dose Level 0. The record does not specify whether these deaths were attributed to treatment, the underlying conditions, or another cause, nor does it provide timing. These entries should not be treated as treatment-related death counts without that context.

12. What the Result Does, and Does Not, Mean

The registry record establishes that a Phase I/Phase II, nonrandomized, sequential study enrolled 23 participants to investigate a combination regimen in relapsed T-ALL and T-LL. It describes a primary safety outcome based on the presence of dose-limiting toxicities and states that assessment was organized by dose level and courses taken. It also explains that not all enrolled participants were considered evaluable for that outcome. These details define the study question and the limits of its analysis population.

The record does not report the observed DLT counts or the number of participants analyzed for the primary endpoint. It therefore does not show how often DLTs occurred or provide an estimate of their frequency. The secondary objective concerning complete remission after 1 and 2 courses is listed, but its results are not reported in the registry record. The available information cannot establish whether the regimen achieved a particular remission outcome.

The serious adverse-event counts and listed event terms provide descriptive safety information, but they do not establish causality or comparative risk. The groups were not randomized, and the record does not explain event attribution or provide a like-for-like control group. The death counts also lack information about cause and timing. A difference between recorded dose-level groups would not, on its own, identify an effect of dose.

These limitations do not negate the study’s role as dose-finding research. They mean that interpretation must remain close to what the record actually documents: trial design, group enrollment, outcome definitions, and selected adverse-event entries. The record does not report the statistical analyses, uncertainty estimates, or outcome details needed for stronger conclusions about the primary endpoint or comparative effects.

13. Why This Trial Matters Statistically

Early dose-finding studies raise statistical questions that differ from those in randomized efficacy trials. This study’s sequential structure makes it important to distinguish the logic of escalating doses from a controlled comparison. Dose levels can inform safety exploration, but nonrandom assignment means the groups are not designed to be directly exchangeable. Statistical interpretation must account for that design rather than treating observed group differences as causal evidence.

The record also highlights why endpoint denominators matter. Enrollment counts are not necessarily the counts analyzed for DLTs: the registry states that some participants were not evaluable and that only eligible participants were counted in the overall analysis. Without the evaluable denominator, a participant count cannot be interpreted as a complete estimate of endpoint frequency. This distinction is central to reading safety results accurately.

Finally, the registry record illustrates the difference between a stated study objective and a reported result. It defines a primary DLT outcome and lists complete remission as a secondary objective, but it does not report the observed primary or secondary outcome results. Transparent interpretation requires recognizing what information is available and what is absent. The record contains descriptive adverse-event entries, yet does not establish event attribution, provide a randomized comparison, or report statistical uncertainty. Those constraints shape the claims that can responsibly be made from this trial record.

14. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The main limitation is that observed primary outcome data are not reported. Although the endpoint is defined as presence of DLTs over 6 months, the record does not give DLT counts, evaluable denominators, or the number analyzed. It also notes that not all enrolled participants were evaluable, while leaving the criteria and reasons for non-evaluability unspecified. This prevents assessment of the primary outcome’s frequency and completeness.

The study was nonrandomized and sequential. Its dose-level groups are therefore not like-for-like control groups, and simple differences between them cannot be interpreted as causal dose effects. The registry record does not report an adjusted analysis, confidence intervals, or other inferential results. The enrollment was 23, with adverse-event groups of 6, 7, and 10 participants at Dose Levels 1, 2, and 3; the record does not establish that these were the primary endpoint analysis denominators.

The serious adverse-event term percentages are listed without a clear denominator or dose-level distribution in the available record. Death counts are listed by dose level, but cause and timing are not reported. The complete remission outcome is named as secondary, but its observed results are not reported. The reason the trial was terminated is also not reported in the registry record. Further protocol details, including the full dose-escalation rules and the statistical analysis plan, are not reported in the registry record.

15. Related Tutorials

16. Related Statistical Calculators

17. Sources

• ClinicalTrials.gov: Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL — NCT00981799.
• Registry record last updated 2020-10-01; status last verified 2020-09.
• Results first posted 2020-10-01.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

18. Record Summary

The registry record describes a Phase I/Phase II, nonrandomized, unmasked, sequential trial of nelarabine, etoposide and cyclophosphamide in children with relapsed T-ALL or T-LL. Enrollment was 23. The study began in 2010-06, had primary completion in 2015-11, and is listed as terminated.

The primary outcome was the presence of DLTs, assessed over 6 months by dose level and courses taken. The record says not all participants were evaluable and does not report the observed DLT results or evaluable denominators. A secondary complete remission objective is listed, without reported results. Adverse-event entries include serious-event counts by dose level and selected event-term percentages, but the record does not establish causal comparisons or provide context for the death counts. No statistical analyses are reported.